EOLS - Evolus to Participate in the SVB Securities Global Biopharma Conference
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the SVB Securities Global Biopharma Conference.
| Event: |
|
|
| SVB Securities Global Biopharma Conference. |
| Date: |
|
|
| Tuesday, February 14, 2023 |
| Time: |
|
|
| 11:20-11:50 am ET |
An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com . A replay of the webcast will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on LinkedIn , Twitter , Instagram or Facebook .
Jeuveau ® is a registered trademark of Evolus, Inc.
Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005470/en/
Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com
Media Contact :
Email: media@evolus.com